Biden Travels to Virginia to Talk Health Care

February 10, 2022 by Alexa Hornbeck
<strong>Biden Travels to Virginia to Talk Health Care</strong>
President Joe Biden speaks with Rep. Abigail Spanberger, D-Va., as he arrives on Marine One at Culpeper Regional Airport, Thursday, Feb. 10, 2022, in Brandy Station, Va. (AP Photo/Alex Brandon)

CULPEPER COUNTY, Va. — President Joe Biden traveled to Culpeper County, Virginia, Thursday delivering remarks intended to revive provisions of his now moribund Build Back Better agenda related to lowering health care costs and, particularly, prescription drug prices.

Mindful of a Labor Department report Thursday that found consumer prices jumped 7.5% last month — the steepest jump in 40 years — Biden said, “Just a little bit more breathing room makes a gigantic difference.” 

During his remarks, Biden said he would take steps to cap co-pays for prescription drugs and impose a “steep tax” on drug companies that raise their prices faster than the rate of inflation once the price is set.

He also said the administration will work to enforce discounts on prescription drugs for rural clinics and community health centers, and bring even more clarity and fewer surprises for those who are hospitalized. 

Biden said this could all be done through the Build Back Better legislation, which passed the House last year but has stalled in the Senate. 

Undeterred, Biden said his message to the big pharmaceutical companies is clear.

“You are finally going to become accountable when you raise prices on the American people,” he said.

According to the White House, one in four Americans who need prescription drugs struggle to afford them, and over the past decade health care costs have gone up about 50%. 

Health and Human Services Secretary Xavier Becerra accompanied the president to Culpeper County, and his remarks focused mainly on how the American Rescue Plan — the COVID-19 stimulus package passed last March — benefitted American consumers.

According to Becerra, about four in five people who recently signed up for health insurance through HealthCare.gov were able to find a plan where they pay less than $10 per month in premiums.

“Now that’s a good deal,” said Becerra.

What’s not a good deal, Becerra said, is that on average insured Americans still pay about $1,500 per person a year on prescription medications.

For months, the Build Back Better plan has appeared to be in the hands of Sen. Joe Manchin, D-W.Va., who announced in December 2021 that he couldn’t support the costly package passed in the House.

In the weeks since, there has been talk on Capitol Hill of a “slimmed down” version of Build Back Better, or a rolling out of its provisions individually, but actual progress on that front has been slow.

And as recently as last week, Manchin told reporters the bill is “dead.”

Biden appeared alongside Rep. Abigail Spanberger, D-Va., who may be in danger of losing her seat representing a central Virginia district.

Spanberger told the Associated Press that she welcomes any effort to lower prescription drug prices and told reporters that the effort was about a broader attempt to reduce inflation.

“That’s part and parcel of what we’re here talking about, right?” she said. “So when you’re worried about the gas pump or you’re worried about the cost of chicken in the grocery store, and your child is diabetic — all those things become impactful.” 

Alexa can be reached at [email protected]

A+
a-
  • Build Back Better
  • inflation
  • Joe Biden
  • Labor Department
  • prescription drug prices
  • Virginia
  • Xavier Becerra
  • In The News

    Health

    Voting

    Prescription Drugs

    April 18, 2025
    by Dan McCue
    Scores of Generic Medications Recalled Over Quality Issues

    WASHINGTON — Nearly 40 different generic medications have been voluntarily recalled by Glenmark Pharmaceuticals after regulators flagged issues related to... Read More

    WASHINGTON — Nearly 40 different generic medications have been voluntarily recalled by Glenmark Pharmaceuticals after regulators flagged issues related to how the drugs were manufactured in India, the Food and Drug Administration announced Friday. To ensure the safety and uniformity of medicines, the FDA has imposed... Read More

    Pfizer Ends Development of Potential Pill Obesity Treatment

    Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level... Read More

    Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver... Read More

    The Skyrocketing Cost of Weight-Loss Drugs Has State Medicaid Programs Looking for a Solution

    States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are searching for ways to... Read More

    States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are searching for ways to get out from under the budgetary squeeze that took them by surprise. One solution some policymakers may try is restricting the number of people on Medicaid... Read More

    FDA Approves Painkiller Designed to Eliminate the Risk of Addiction Associated With Opioids

    WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of... Read More

    WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or... Read More

    January 29, 2025
    by Tom Ramstack
    Kennedy Downplays Vaccine Statements During Health Dept. Confirmation Hearing

    WASHINGTON — Robert F. Kennedy Jr. tried to deflect accusations of being a junk science advocate Wednesday during his Senate... Read More

    WASHINGTON — Robert F. Kennedy Jr. tried to deflect accusations of being a junk science advocate Wednesday during his Senate confirmation hearing to become secretary of the U.S. Department of Health and Human Services. Much of his time was spent defending his previous statements against vaccines... Read More

    J&J Buys Intra-Cellular in $14.6B Deal, Delving Further Into Central Nervous System Disorders

    Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders... Read More

    Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said Monday that it will pay $132 in cash for each share of Intra-Cellular. That represents a 39%... Read More

    News From The Well
    scroll top